BASTA JAMES 4

What Happened

• James Basta, EVP and General Counsel of Intellia Therapeutics (NTLA), received equity awards on March 1, 2026: 46,080 restricted stock units (RSUs) and a derivative award of 65,829 shares (an option-like award). Both awards were granted at $0.00 value. Following the RSU vesting, a mandatory sell-to-cover transaction on March 2, 2026 disposed of 1,211 shares at $13.78 each, netting $16,688 to satisfy tax withholding.

Key Details

• Transactions and prices:
  • 2026-03-01: Award of 46,080 RSUs (grant, $0.00) — each RSU represents a contingent right to one share (Footnote F1).
  • 2026-03-01: Grant of 65,829 derivative award (reported as A, $0.00) — described as an option with vesting: 33% on Jan 1, 2027, remainder vesting monthly over the following 24 months (Footnote F3).
  • 2026-03-02: Sale of 1,211 shares @ $13.78 = $16,688 (mandatory sell-to-cover to satisfy tax withholding upon RSU vesting; Footnote F2).
• Shares owned after the transactions: Not specified in this Form 4 filing.
• Filing timeliness: Form filed 2026-03-03 for transactions on 2026-03-01 and 03-02; the filing appears timely (no late filing flag in the report).
• Footnotes of note:
  • F1: RSUs equal a contingent right to one share each.
  • F2: The 1,211-share sale was a mandatory sell-to-cover for taxes and not a discretionary trade.
  • F3: The 65,829-unit derivative grant is an option with a multi-year vesting schedule.

Context

• This filing mainly reflects compensation-related equity grants (RSUs and an option-like award) rather than a market-directional purchase. The small sale was a routine, mandatory sell-to-cover for tax withholding and should not be read as a voluntary sell signal.
• The derivative award has future vesting conditions; those shares/options are not immediately liquid and will vest according to the schedule in F3.